GlaxoSmithKline expands herpes zoster vaccine indications to children aged 18 and above
October 29, 2025
Source: drugdu
76
On October 14, a reporter from Interface News learned from GlaxoSmithKline that the China National Medical Products Administration has approved Shingrix (GlaxoSmithKline's recombinant herpes zoster vaccine (CHO cells)) for the prevention of herpes zoster in adults aged 18 and above who have an increased risk of developing herpes zoster due to immunodeficiency or immunosuppression caused by known diseases or treatments (such as autologous hematopoietic stem cell transplantation).
To date, Shingrix is the first and only vaccine approved by the China National Medical Products Administration for use in this population. This approval builds on the previous expansion of its indication for adults aged 50 and above.
https://finance.eastmoney.com/a/202510143533562628.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
